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sociated with a greater decline on all tests, after adjustment. 
Findings were statistically significant for the TICS and cate-
gory fluency, e.g. the multivariable-adjusted mean differ-
ence (95% CI) in decline for men with the highest versus low-
est insulin levels was –0.62 (–1.15, –0.09) points on the TICS 
(p for trend = 0.04); this difference was similar to that be-
tween men 7 years apart in age. Similarly, there was a great-
er decline across all tests with increasing C-peptide, but the 
findings were statistically significant only for the global 
score (p for trend = 0.03).  Conclusions:  Higher fasting insulin 
and greater insulin secretion in older men may be related to 
overall cognitive decline, even in the absence of diabetes. 
  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
  Type 2 diabetes, initially characterized by insulin re-
sistance and hyperinsulinemia, has been identified as a 
risk factor for cognitive decline and dementia   [1] .  How-
ever, it is difficult to disentangle the impact of hyperin-
sulinemia from the effect of sequelae that accompany di-
abetes itself. Thus, in prior work, we addressed the rela-
tion of elevated insulin secretion and fasting insulin 
levels to cognition among community-dwelling, healthy 
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 Abstract 
  Background:   Type 2 diabetes has been associated with 
  diminished late-life cognition; less is known about relations 
of insulin levels and insulin secretion to cognitive change 
among persons without diabetes. We examined prospec-
tively relations of fasting insulin levels and insulin secretion 
to cognitive decline among healthy, community-dwelling 
older men without diabetes.  Methods:   Fasting plasma insu-
lin and C-peptide (insulin secretion) levels were measured in 
1,353 nondiabetic men, aged 60–92 years (mean = 71.3 
years), in the Physicians’ Health Study II, who participated in 
cognitive testing an average of 3.3 years later. Two assess-
ments were administered 2 years apart (range = 1.5–4.0 
years) using telephone-based tests (general cognition, ver-
bal memory and category fluency). Primary outcomes were 
the Telephone Interview for Cognitive Status (TICS), global 
cognition (averaging all tests) and verbal memory (averag-
ing 4 verbal tests). Multivariable linear regression models 
were used to estimate the relations of insulin and C-peptide 
to cognitive decline.   Results:   Higher fasting insulin was as-
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elders without diabetes. We recently found that both el-
evated midlife fasting insulin and C-peptide levels were 
significantly associated with late-life cognitive decline in 
a large, random sample of nondiabetic women in the 
Nurses’ Health Study. These relations were not affected 
by adjustment for vascular factors such as hypertension, 
dyslipidemia and heart disease. However, since some of 
the deleterious effects of diabetes are more serious in 
women than men   [2, 3]  , our findings in women are not 
necessarily generalizable to men. Thus, in the current 
study, we measured fasting plasma levels of insulin and 
C-peptide in a random sample of 1,353 older men without 
diabetes, from the well-characterized Physicians’ Health 
Study II (PHS-II)   [4, 5]   cohort, and then related these 
measures to subsequent cognitive change. 
  M e t h o d s  
  Physicians’ Health Study 
  The PHS-I was a randomized, double-blind, placebo-con-
trolled, 2   !   2 factorial trial of aspirin and     -carotene for the pri-
mary prevention of cardiovascular disease (CVD) and cancer in 
men. Beginning in 1982, 22,071 US male licensed physicians, then 
aged 40–84 years, were randomized to 1 of 4 factorial groups. 
Thereafter, they were followed annually, via mailed self-reported 
questionnaires, to ascertain endpoints, lifestyle and health-relat-
ed factors  [6, 7] . The PHS-II  [4, 5]  randomized trial began in 1997 
and was completed on August 31, 2007. An extension of the PHS-
I, it examined the prevention of CVD, cancer and age-related eye 
diseases with vitamin supplements in 14,641 men, of whom 7,641 
were original participants of the PHS-I. Morbidity and mortality 
follow-up outcomes in the PHS-II were extremely high at 95.3% 
and 97.7%, respectively   [4, 5] .
    Between 1995 and 2001, blood samples were obtained from 
11,133 (76%) of the 14,641 PHS-II participants. The participants 
were sent blood collection kits containing the following: (a) 3 
EDTA and 3 citrate tubes; (b) a gel-filled freezer pack; (c) a com-
pleted overnight courier air bill, and (d) written instructions and 
other supplies needed for venipuncture. Specimens were sent to 
our laboratory in freezer packs within 24 h of blood draw. Once 
received, the samples were fractionated into plasma, red blood 
cells and buffy coat, and then frozen at –170    °   C. The entire process 
was completed swiftly to ensure that the samples were frozen 
within 30–36 h after venipuncture; precautions were taken to pre-
vent the thawing or warming of specimens during storage   [8, 9] . 
    Ascertainment of Plasma Insulin and C-Peptide Levels 
  Using stored blood samples obtained after a   6  8-hour fast, we 
measured plasma insulin, using a radioimmunoassay specific for 
insulin (Linco, St. Louis, Mo., USA) based on an antiserum with 
  ! 1% cross-reactivity for proinsulin and des-31,32-proinsulin, and 
plasma C-peptide, using antiserum M1230 in an alcohol precipi-
tation nonequilibrium assay  [10]  with reagents provided by Diag-
nostic Systems Laboratory (Webster, Tex., USA). The assays were 
conducted in a single batch. Aliquots from a pool of quality-con-
trol plasma were randomly inserted into the batch of samples. The 
intra-assay coefficients of variation for insulin and C-peptide 
from these 57 blinded quality-control pairs were 6.8 and 7.2%, 
respectively.
  Cognitive  Function  Assessment 
  Starting in 1998, cognitive testing began among 6,773 eligible 
PHS-II participants aged 65 years or older. There was an 88% par-
ticipation (5,953 men) among those eligible. A second wave of 
testing was conducted 2 years later, with an 88% follow-up 
achieved among those who completed the baseline testing   [11] .
    The cognitive interview consisted of 5 tests: (1) the Telephone 
Interview for Cognitive Status (TICS); (2) the immediate-recall 
and (3) delayed-recall trials of the East Boston Memory Test 
(EBMT); (4) the delayed-recall trial of the TICS 10-word list, and 
(5) category fluency. The TICS (scores range from 0 to 41 points) 
  [12]   is a telephone-administered instrument similar to the Mini-
Mental State Examination   [13]  ; it has a high reliability and valid-
ity for measuring general cognition   [12]  . The EBMT   [14]   is a ver-
bal memory (paragraph recall) task and involves immediate and 
15- to 20-min-delayed recalls (scores range from 0 to 12 points). 
The 20-min-delayed recall of the TICS 10-word list also assesses 
verbal memory (scores range from 0 to 10 points). Lastly, in the 
category fluency test, subjects name as many different animals as 
possible in 1 min. Category fluency captures language, and be-
cause it involves abstract conceptualization and strategy, it also 
maps to the domain of executive function  [15] . All tests were con-
ducted over the phone by trained interviewers blind to the study 
hypotheses.
  The reliability and validity of this telephone method have been 
established   [16]  . The 30-day test-retest reliability (r = 0.7) and in-
terrater reliability (r   6   0.95 for each test) are high. The global 
score from the telephone battery correlated strongly (r = 0.81) 
with a global score generated from 21 in-person neuropsycho-
logical tests. Furthermore, recent validation work has demon-
strated that low telephone-based global scores are significantly 
associated with an 8-fold risk of dementia diagnosis by blinded 
neurologists.
    Measurement of Covariates and Potential Confounders 
 Information on a variety of medical conditions (e.g. hyperten-
sion and diabetes), lifestyle factors (e.g. smoking, exercise and al-
cohol use) and medications (e.g. elevated cholesterol treatment) 
was obtained from the annually mailed self-report questionnaires 
  [17]  . Self-reports have proven highly accurate among male health 
professional participants   [17, 18] .
    Determination of Sample for Analysis 
  We measured insulin and C-peptide in a random sample of 
1,353 PHS-II cognitive study participants who had provided 
blood samples and had no self-reported history of diabetes as of 
the time of their first cognitive interview. For the analyses of fast-
ing insulin, the sample included 1,314 participants as 39 men had 
insulin levels below the assay limit of detection (2    IU/ml).
    Informed consent was obtained from all participants. The 
current study and the overall PHS-II study were approved by the 
Institutional Review Board of Brigham and Women’s Hospital 
(Boston, Mass., USA). Okereke   /Kurth   /Pollak   /Gaziano   /
Grodstein    
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  S t a t i s t i c a l   A n a l y s i s  
 Study  Outcomes 
  The primary outcomes were general cognitive function and 
verbal memory, a strong predictor of Alzheimer disease   [19, 20] . 
For assessing general cognition, we considered the TICS and the 
global score combining all 5 cognitive tests. This global score was 
calculated by averaging the Z scores from each test. Verbal mem-
ory was calculated by combining the results of the verbal memory 
tests (immediate and delayed recalls of the EBMT and 10-word 
list), also using Z scores. Composite scores are regularly used in 
cognitive research   [21, 22]   as they integrate information from a 
variety of sources. 
  We examined category fluency as a secondary outcome, as ex-
ecutive function is related to vascular factors  [23]  and is of interest 
in considering possible cognitive effects of higher levels of insulin 
or C-peptide.
  Overall  Analysis 
  The distributions of insulin and C-peptide were found to be 
severely right-skewed. Of note, we had previously identified only 
a mild skew of C-peptide in the PHS cohort when blood samples 
were taken at a mean age of 57 years   [24]  . Thus, the distributions 
in the present study of PHS men with a mean age of 71.3 years 
(range = 60–92 years) at blood draw were consistent with those of 
men in the Honolulu-Asia Aging Study   [25]  , who had a mean age 
of 77 years at blood draw. 
    Given these nonnormal distributions, the insulin and C-pep-
tide values were natural log transformed. For the analysis, we then 
created 4 categories according to the distance (log SD) from the 
log mean   [25]  : (1) values   !  1 log SD below the log mean; (2) values 
below the log mean but within 1 log SD; (3) values above the log 
mean but within 1 log SD, and (4) values   1  1 log SD above the log 
mean. We used linear regression models to estimate the age- and 
multivariable-adjusted mean differences in cognitive change 
across these 4 categories. The categorical analyses allowed us to 
examine whether an inverse U-shaped relation may exist between 
insulin measures and cognitive change, which has been reported 
  [25] . Since no U-shaped relations were observed, we tested for lin-
ear trends by examining insulin and C-peptide as continuous 
variables, where the unit of analysis was a 1-log-SD increase in 
insulin or C-peptide. 
    All statistical analyses were performed using SAS  ©   version 9.1 
(SAS Institute Inc., Cary, N.C., USA). Statistical tests were two-
sided with      set at 0.05.
    Analyses of Covariates and Potential Confounders 
 In the linear regression models, we included the following: age 
(years), history of hypertension (yes, no), history of dyslipidemia 
(yes, no), history of confirmed major CVD event (heart attack or 
stroke; yes, no), history of depression (self-reported diagnosis of 
depression or antidepressant treatment; yes, no), cigarette smok-
ing (never, current, past), alcohol intake (never/rare, 1–6 drinks 
per week,   6  1 drinks per day), body mass index and frequency of 
vigorous exercise (never/rare, 1–4 times per week,   6  5 times per 
week). We did not adjust for education as this was identical across 
our sample of physicians. Information on covariates was deter-
mined from questionnaires nearest to the time of blood collect-
ion – except age, CVD and depression, which were determined as 
of the start of cognitive testing.
  R e s u l t s  
  Sample Characteristics by Insulin and C-Peptide 
Levels 
  The participants’ characteristics demonstrated ex-
pected associations with both plasma fasting insulin and 
C-peptide (  tables 1  ,   2  ). Increasing insulin and C-peptide 
were both associated with an increasing prevalence of hy-
pertension, dyslipidemia and heart disease. Daily alcohol 
intake was most prominent among those with the lowest 
fasting insulin levels. Trends of increasing age, depres-
sion prevalence, lower physical activity and obesity were 
more consistent for increasing C-peptide than for in-
creasing insulin; only 2 men in the lowest C-peptide 
group were obese.
    Prospective Analyses of Cognitive Decline 
    Figure 1   depicts the results for cognitive change ac-
cording to fasting insulin levels. Overall, a greater cogni-
tive decline was observed at higher versus lower levels of 
insulin. There were significant multivariable-adjusted 
associations between higher fasting insulin and decline 
on the TICS scale (p for trend = 0.04). To help interpret 
the mean difference of –0.62 points (95% CI: –1.15, –0.09) 
between those with the highest versus lowest levels of in-
sulin, we contrasted it with the estimate for age. Each ad-
ditional year of age was associated with a mean decline of 
0.09 points (p   !   0.0001) on the TICS scale; thus, those in 
the group with the highest fasting insulin had declines 
equivalent to those we observed for subjects approxi-
mately 7 years older. There was a nonsignificant trend 
between higher fasting insulin and decline on the global 
score (p = 0.10), and there was a borderline significant 
mean difference (95% CI) comparing extreme insulin 
quartiles of –0.11 units (–0.23, 0.01; p = 0.08). On catego-
ry fluency, there was a significantly greater decline com-
paring men with the highest versus lowest fasting insulin 
levels (mean difference again comparable to subjects 7 
years older); however, the association was slightly stron-
ger when adjusted only for age, i.e. a mean difference 
(95% CI) of –1.29 words (–2.29, –0.28; data not shown in 
table), compared to a mean difference of –1.15 (–2.24,
–0.06) after control for CVD and risk factors. An attenu-
ation after adjustment for vascular factors was only ob-
served for the category fluency outcome. There was no 
association between fasting insulin and verbal memory.
    Differences in cognitive change according to C-pep-
tide levels are shown in  figure 2 . As observed with fasting 
insulin, there was an overall pattern of greater cognitive 
decline comparing those with the highest to those with   Fasting Plasma Insulin, C-Peptide and 
Cognitive Change in Older Men 
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Table 2. Characteristics of sample at blood draw, by fasting C-peptide levels
<0.38 nmol/l 0.38–0.60 nmol/l 0.60–0.94 nmol/l >0.94 nmol/l
Participants, n 187 (13.8) 509 (37.6) 458 (33.9) 199 (14.7)
Geometric mean C-peptide level, nmol/l 0.31 0.48 0.73 1.27
Geometric mean insulin level, IU/ml 3.48 4.52 6.54 13.18
Mean age 8 SD, years 71.186.0 71.385.7 71.185.8 71.986.0
History of hypertension, % 31.0 40.2 48.0 62.3
History of elevated total cholesterol, % 20.1 26.2 29.5 35.7
Current smoking, % 1.1 2.8 2.6 2.5
Past smoking, % 44.1 44.0 48.1 52.3
Depression, % 8.6 7.7 10.9 11.1
History of cardiovascular disease, % 7.5 6.7 11.4 14.6
Physical activity, %
≥5 times per week 22.2 17.9 21.0 15.2
1–4 times per week 51.4 43.9 39.5 35.5
Alcohol, %
≥1 drinks per day 42.5 41.5 40.2 39.1
1–6 drinks per week 30.1 30.8 30.6 34.5
Mean body mass index score 8 SD 23.482.7 25.082.5 26.483.4 27.884.2
Body mass index ≥30, % 1.1 3.9 12.3 21.7
Groups are based on 1-SD distances from the sample log mean (geometric sample log mean = 0.60 nmol/l), and cutoff values are 
presented after natural log back-transformation. Values in parentheses denote percentages.
Table 1. Characteristics of sample at blood draw, by fasting insulin levels
<3.3 IU/ml 3.3–5.9 IU/ml 5.9–10.3 IU/ml >10.3 IU/ml
Participants, n 188 (14.3) 557 (42.4) 384 (29.2) 185 (14.1)
Geometric mean insulin level, IU/ml 2.82 4.51 7.47 16.23
Geometric mean C-peptide level, nmol/l 0.41 0.52 0.70 1.14
Mean age 8 SD, years 71.585.9 71.185.8 71.585.8 71.285.6
History of hypertension, % 37.8 43.4 45.8 61.1
History of elevated total cholesterol, % 16.7 28.1 31.4 34.1
Current smoking, % 2.1 2.3 2.6 3.2
Past smoking, % 49.5 44.3 47.7 47.6
Depression, % 10.6 9.2 8.6 9.7
History of cardiovascular disease, % 6.9 7.9 10.7 15.1
Physical activity, %
≥5 times per week 16.8 19.6 19.0 19.7
1–4 times per week 51.4 41.3 42.6 32.2
Alcohol, %
≥1 drinks per day 47.9 41.5 37.3 36.6
1–6 drinks per week 27.7 31.8 31.3 33.9
Mean body mass index score 8 SD 23.882.6 25.182.7 26.583.4 28.284.2
Body mass index ≥30, % 4.3 3.8 13.0 22.8
Groups are based on 1-SD distances from the sample log mean (geometric sample log mean = 5.9 IU/ml), and cutoff values are 
presented after natural log back-transformation. Values in parentheses denote percentages. Okereke   /Kurth   /Pollak   /Gaziano   /
Grodstein    
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the lowest C-peptide levels. The mean difference in de-
cline, comparing the extreme C-peptide groups, was sta-
tistically significant for the global score (p for trend = 
0.03); this was cognitively equivalent to aging by about 5.5 
years. The mean decline in verbal memory associated 
with the highest C-peptide group was borderline signifi-
cant compared to those with the lowest C-peptide (mean 
difference = –0.13; p = 0.07). As with fasting insulin, there 
was a notable attenuation of estimates relating C-peptide 
to change in category fluency scores after adjustment for 
vascular factors. There was, for instance, a significant 
age-adjusted trend to a greater decline in category flu-
ency with increasing C-peptide (p for trend = 0.02); how-
ever, the trend was borderline significant (p for trend = 
0.07) after multivariable adjustment.
  D i s c u s s i o n  
  In this random sample of 1,353 community-dwelling 
older men without diabetes, higher late-life levels of fast-
ing insulin and C-peptide were associated with a greater 
subsequent decline in general cognition. For example, the 
multivariable-adjusted mean difference (95% CI) in de-
cline for men with the highest versus lowest fasting insu-
lin was cognitively equivalent to that observed between 
men 7 years apart in age. Similarly, the decline on the 
global score for men with the highest versus lowest C-
peptide levels was cognitively comparable to the effect of 
aging by 5.5 years.
  Several  observational  studies   [24, 26–30]   have  identi-
fied cross-sectional associations between hyperinsu-
linemia (or measures of insulin resistance) and impaired 
late-life cognitive performance. However, only few large 
studies  [25, 31–34]  have prospectively addressed relations 
of insulin to cognitive change over time among older 
adults. Luchsinger et al.   [31]   reported that higher fasting 
insulin was associated with a significant decline in mem-
ory scores in a cohort of older men and women. Simi-
larly, Yaffe et al.   [32]   found that older women without 
diabetes but with impaired fasting glucose (an indicator 
of growing insulin resistance) had a relative risk of 1.64 
(95% CI: 1.03, 2.61) for developing significant cognitive 
impairment (defined as dementia, mild cognitive impair-
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  Fig. 1.   Multivariable-adjusted mean differences in change in cog-
nitive performance, by fasting insulin levels. Adjusted for age 
(years), hypertension (yes, no), history of dyslipidemia (yes, no), 
history of heart disease (yes, no), history of depression (yes, no), 
cigarette smoking (current, past, never), body mass index (score), 
alcohol intake (never/rare, weekly, daily) and physical activity 
(high, moderate, low/never). Group cutoff values are presented 
after natural log back-transformation.  *  Mean difference is statis-
tically significant.    Fasting Plasma Insulin, C-Peptide and 
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ment or a Short Blessed   [35]   score of   1  6) after 4 years of 
follow-up compared to those with normal glucose; how-
ever, impaired fasting glucose was not associated with a 
significantly greater decline on individual cognitive tests. 
Finally, recent work involving over 1,000 women from 
the Nurses’ Health Study has focused on midlife bio-
markers, but has also found that higher fasting insulin 
  [34]   and C-peptide   [33]   were associated with increased 
rates of decline in late-life overall cognition and verbal 
memory. A notable contrast between these prior results 
  [33, 34]   and those from the current study was the strong 
relation of elevated levels of both insulin and C-peptide 
to verbal memory decline among women. This may sug-
gest a possible gender difference worth further scrutiny 
in studies involving direct comparisons (i.e. whether ver-
bal memory is more sensitive to insulin-dysregulation-
related cognitive decline among women vs. men). Over-
all, the results of the current study are consistent with 
emerging evidence suggesting that higher insulin levels 
are related to general cognitive decline in both older 
women and men, even in the absence of diabetes.
    Higher insulin levels may impact cognition through a 
variety of mechanisms including vascular damage associ-
ated with insulin resistance   [29, 36]  ; our results for cate-
gory fluency are consistent with this potential explana-
tion. Specifically, we observed that estimates of associa-
tions between insulin and category fluency decline were 
substantively attenuated after adjustment for CVD and 
other vascular factors. As a task that maps to the executive 
function domain, category fluency is most likely among 
the tests in our battery to be affected by vascular factors; 
in fact, executive dysfunction is a prominent feature
of vascular cognitive impairment and/or dementia   [23] . 
However, we did not observe a similar attenuation of esti-
mates for the other cognitive outcomes, suggesting that an 
intermediary influence of vascular pathology is unlikely 
to be the major explanation for our findings relating insu-
lin and C-peptide levels to overall cognitive decline. In-
deed, growing biological evidence suggests more direct 
effects of higher insulin. Insulin is a competitive inhibitor 
for insulin-degrading enzyme   [37] ;  therefore,  persistent 
elevations in insulin may interfere with peripheral A    
clearance, and this could lead to higher A   concentrations 
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  Fig. 2.  Multivariable-adjusted mean differences in change in cog-
nitive performance, by fasting C-peptide levels. Adjusted for age 
(years), hypertension (yes, no), history of dyslipidemia (yes, no), 
history of heart disease (yes, no), history of depression (yes, no), 
cigarette smoking (current, past, never), body mass index (score), 
alcohol intake (never/rare, weekly, daily) and physical activity 
(high, moderate, low/never). Group cutoff values are presented 
after natural log back-transformation.  *  Mean difference is statis-
tically significant.  Okereke   /Kurth   /Pollak   /Gaziano   /
Grodstein    
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